Position in NVCT
as of Mar 31, 2026
· filed Apr 24, 2026
Position Value
$5,038,081
+$611,365 QoQ
Shares Held
651,757
+11.2% QoQ
Ownership
2.46%
of shares outstanding
% of Portfolio
2.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026IRIDIAN ASSET MANAGEMENT LLC/CT holds $35,697,443 across 7 Biotechnology names. NVCT ranks #3 (14.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PGEN |
Precigen, Inc.
|
3,592,730 | $13,903,865 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
67,491 | $11,407,328 | |
| 3 | NVCT |
Nuvectis Pharma, Inc.
This page
|
651,757 | $5,038,081 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
75,289 | $2,501,100 | |
| 5 | NKTR |
Nektar Therapeutics
|
31,320 | $2,253,474 | |
| 6 | ELTX |
Elicio Therapeutics, Inc.
|
30,051 | $321,245 | |
| 7 | BCTX |
BriaCell Therapeutics Corp.
|
65,000 | $272,350 |
All Filings in NVCT
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,038,081 | 651,757 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $4,426,716 | 586,320 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $2,441,838 | 405,621 | Shares | Sole | 2025-10-24 | |
| 2025-06-30 | $2,784,195 | 372,717 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $2,481,306 | 253,972 | Shares | Sole | 2025-04-30 | |
| 2024-09-30 | $348,340 | 55,380 | Shares | Sole | 2024-10-25 | |
| No filing history on record for this holder in this stock. | ||||||